One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2021-145276
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 4 |
Affiliation: Roswell Park Cancer Institute, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Tufts University, University of Kansas Cancer Center, Alberta Hospital Edmonton, University of California, Los Angeles, Mayo Clinic, Princess Margaret Cancer Centre, Cornell University, Ark Therapeutic (United States)A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
